

## REMARKS

In response to the restriction requirement, Applicants elect, without traverse, to prosecute claims 1-10, 24 and 25, *i.e.*, the Group I claims. Accordingly, claims 11-23 and 26-30 have been withdrawn and are subject to re-joinder upon the allowance of a suitable linking claim.

With respect to the requested species restriction election, Applicants elect as follows:

The receptor polypeptide as shown in SEQ ID NO: 12; encoded by the corresponding nucleic acid sequence of SEQ ID NO: 11 (Claim 9(a) and (b), respectively).

This receptor comprises the third intracellular loop as depicted in SEQ ID NO: 18; encoded by the corresponding nucleic acid sequence as depicted in SEQ ID NO: 17 (Claim 10(a) and (b), respectively).

Moreover, it may comprise the FRET-pair YFP and CFP (claim 8), which are preferably "fluorescent labels" (claim 7).

The elected receptor is an "alpha2A adrenergic receptor" (claim 5) which belongs to the group of "G-protein-coupled receptors" ((GPCRs); claim 3), in particular to the group of "rhodopsin/beta2 adrenergic receptor-like GPCRs" (claim 4).

Within the elected receptor the two detectable label are located at the third intracellular loop and the carboxy terminus (claim 2). In particular CFP is located at the third intracellular loop and YFP is located at the carboxy terminus (see Fig. 1A).

Applicants believe that all of the pending claims under examination read on the foregoing restricted species.

Claims 1-10, 24 and 25 are thus pending and under examination.

The Examiner is invited to contact the undersigned attorney at (512) 536-3055 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: November 13, 2008